NCT04540120 - Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

July 28, 2022

Study Completion Date

July 28, 2022

Conditions

Covid19Cytokine Release Syndrome

Interventions

DRUG

dapansutrile capsules

Hard opaque capsules containing 250 mg of API.

DRUG

placebo capsules

Hard opaque capsules containing 0 mg of API.

Trial Locations (10)

Inpatient Research Clinic, LLC, Hialeah

C&R Research Services USA, Coral Gables

Invesclinic U.S. LLC, Fort Lauderdale

Sunrise Research Institute, Sunrise

C&R Research Services USA, Houston

J & S Studies, Inc., College Station

Texas Research Alliance LLC, McAllen

PanAmerican Clinical Research LLC, Brownsville

Las Vegas Medical Research, LLC, Las Vegas

University Hospital Basel, Basel